Newborn screening for X-linked adrenoleukodystrophy (X-ALD)

Validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method

Walter C. Hubbard, Ann B. Moser, Anita C. Liu, Richard O. Jones, Steven J. Steinberg, Fred Lorey, Susan R. Panny, Robert F. Vogt, Daniela Macaya, Coleman T. Turgeon, Silvia Tortorelli, Gerald V Raymond

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Newborn screening for X-linked adrenoleukodystrophy (X-ALD) has until now been limited in implementation because of the lack of an accepted standard methodology. We have previously reported a technique using LC-MS/MS analysis that could provide the basis for screening of newborns for X-ALD. The target analyte diagnostic for X-ALD and other peroxisomal disorders of peroxisomal β-oxidation is 1-hexacosanoyl-2-lyso-sn-3-glycero-phosphorylcholine (26:0-lyso-PC). We report here the validation of the analytical method using an authentic standard of the target compound. The method possesses sensitivity of <1.0 fmole injected on column with a correlation coefficient (R2) of 0.9987. A tetradeuterated analog of 26:0-lyso-PC served as the internal standard. The sensitivity of this clinical method was confirmed using 17 newborn samples of individuals with peroxisomal disorders retrieved from state newborn screening programs. These samples were run masked with over 1000 newborn samples. All affected individuals were identified with one exception. One sample which was retrieved as an affected did not have the biochemical or genetic abnormality of X-ALD and thus is considered an error in sample identity. These studies clearly show that the method is highly sensitive and accurate in identifying individuals with a defect in peroxisomal β-oxidation such as X-ALD.

Original languageEnglish (US)
Pages (from-to)212-220
Number of pages9
JournalMolecular Genetics and Metabolism
Volume97
Issue number3
DOIs
StatePublished - Jul 1 2009

Fingerprint

Adrenoleukodystrophy
Liquid chromatography
Liquid Chromatography
Screening
Peroxisomal Disorders
Oxidation
Phosphorylcholine
Defects
Molecular Biology

Keywords

  • 1-Hexacosanoyl-2-lysophosphorylcholine (26:0-lyso-PC)
  • Combined liquid chromatography-tandem mass spectrometry (LC-MS/MS)
  • Lyso-phosphatidyl-choline (lyso-PC)
  • Multiple reaction monitoring (MRM)
  • Newborn screening
  • Peroxisomal disorders
  • Phospholipids
  • X-ALD

Cite this

Newborn screening for X-linked adrenoleukodystrophy (X-ALD) : Validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. / Hubbard, Walter C.; Moser, Ann B.; Liu, Anita C.; Jones, Richard O.; Steinberg, Steven J.; Lorey, Fred; Panny, Susan R.; Vogt, Robert F.; Macaya, Daniela; Turgeon, Coleman T.; Tortorelli, Silvia; Raymond, Gerald V.

In: Molecular Genetics and Metabolism, Vol. 97, No. 3, 01.07.2009, p. 212-220.

Research output: Contribution to journalArticle

Hubbard, WC, Moser, AB, Liu, AC, Jones, RO, Steinberg, SJ, Lorey, F, Panny, SR, Vogt, RF, Macaya, D, Turgeon, CT, Tortorelli, S & Raymond, GV 2009, 'Newborn screening for X-linked adrenoleukodystrophy (X-ALD): Validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method', Molecular Genetics and Metabolism, vol. 97, no. 3, pp. 212-220. https://doi.org/10.1016/j.ymgme.2009.03.010
Hubbard, Walter C. ; Moser, Ann B. ; Liu, Anita C. ; Jones, Richard O. ; Steinberg, Steven J. ; Lorey, Fred ; Panny, Susan R. ; Vogt, Robert F. ; Macaya, Daniela ; Turgeon, Coleman T. ; Tortorelli, Silvia ; Raymond, Gerald V. / Newborn screening for X-linked adrenoleukodystrophy (X-ALD) : Validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. In: Molecular Genetics and Metabolism. 2009 ; Vol. 97, No. 3. pp. 212-220.
@article{3997421bdb7b4fcb8c93da7909ac1fbe,
title = "Newborn screening for X-linked adrenoleukodystrophy (X-ALD): Validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method",
abstract = "Newborn screening for X-linked adrenoleukodystrophy (X-ALD) has until now been limited in implementation because of the lack of an accepted standard methodology. We have previously reported a technique using LC-MS/MS analysis that could provide the basis for screening of newborns for X-ALD. The target analyte diagnostic for X-ALD and other peroxisomal disorders of peroxisomal β-oxidation is 1-hexacosanoyl-2-lyso-sn-3-glycero-phosphorylcholine (26:0-lyso-PC). We report here the validation of the analytical method using an authentic standard of the target compound. The method possesses sensitivity of <1.0 fmole injected on column with a correlation coefficient (R2) of 0.9987. A tetradeuterated analog of 26:0-lyso-PC served as the internal standard. The sensitivity of this clinical method was confirmed using 17 newborn samples of individuals with peroxisomal disorders retrieved from state newborn screening programs. These samples were run masked with over 1000 newborn samples. All affected individuals were identified with one exception. One sample which was retrieved as an affected did not have the biochemical or genetic abnormality of X-ALD and thus is considered an error in sample identity. These studies clearly show that the method is highly sensitive and accurate in identifying individuals with a defect in peroxisomal β-oxidation such as X-ALD.",
keywords = "1-Hexacosanoyl-2-lysophosphorylcholine (26:0-lyso-PC), Combined liquid chromatography-tandem mass spectrometry (LC-MS/MS), Lyso-phosphatidyl-choline (lyso-PC), Multiple reaction monitoring (MRM), Newborn screening, Peroxisomal disorders, Phospholipids, X-ALD",
author = "Hubbard, {Walter C.} and Moser, {Ann B.} and Liu, {Anita C.} and Jones, {Richard O.} and Steinberg, {Steven J.} and Fred Lorey and Panny, {Susan R.} and Vogt, {Robert F.} and Daniela Macaya and Turgeon, {Coleman T.} and Silvia Tortorelli and Raymond, {Gerald V}",
year = "2009",
month = "7",
day = "1",
doi = "10.1016/j.ymgme.2009.03.010",
language = "English (US)",
volume = "97",
pages = "212--220",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Newborn screening for X-linked adrenoleukodystrophy (X-ALD)

T2 - Validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method

AU - Hubbard, Walter C.

AU - Moser, Ann B.

AU - Liu, Anita C.

AU - Jones, Richard O.

AU - Steinberg, Steven J.

AU - Lorey, Fred

AU - Panny, Susan R.

AU - Vogt, Robert F.

AU - Macaya, Daniela

AU - Turgeon, Coleman T.

AU - Tortorelli, Silvia

AU - Raymond, Gerald V

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Newborn screening for X-linked adrenoleukodystrophy (X-ALD) has until now been limited in implementation because of the lack of an accepted standard methodology. We have previously reported a technique using LC-MS/MS analysis that could provide the basis for screening of newborns for X-ALD. The target analyte diagnostic for X-ALD and other peroxisomal disorders of peroxisomal β-oxidation is 1-hexacosanoyl-2-lyso-sn-3-glycero-phosphorylcholine (26:0-lyso-PC). We report here the validation of the analytical method using an authentic standard of the target compound. The method possesses sensitivity of <1.0 fmole injected on column with a correlation coefficient (R2) of 0.9987. A tetradeuterated analog of 26:0-lyso-PC served as the internal standard. The sensitivity of this clinical method was confirmed using 17 newborn samples of individuals with peroxisomal disorders retrieved from state newborn screening programs. These samples were run masked with over 1000 newborn samples. All affected individuals were identified with one exception. One sample which was retrieved as an affected did not have the biochemical or genetic abnormality of X-ALD and thus is considered an error in sample identity. These studies clearly show that the method is highly sensitive and accurate in identifying individuals with a defect in peroxisomal β-oxidation such as X-ALD.

AB - Newborn screening for X-linked adrenoleukodystrophy (X-ALD) has until now been limited in implementation because of the lack of an accepted standard methodology. We have previously reported a technique using LC-MS/MS analysis that could provide the basis for screening of newborns for X-ALD. The target analyte diagnostic for X-ALD and other peroxisomal disorders of peroxisomal β-oxidation is 1-hexacosanoyl-2-lyso-sn-3-glycero-phosphorylcholine (26:0-lyso-PC). We report here the validation of the analytical method using an authentic standard of the target compound. The method possesses sensitivity of <1.0 fmole injected on column with a correlation coefficient (R2) of 0.9987. A tetradeuterated analog of 26:0-lyso-PC served as the internal standard. The sensitivity of this clinical method was confirmed using 17 newborn samples of individuals with peroxisomal disorders retrieved from state newborn screening programs. These samples were run masked with over 1000 newborn samples. All affected individuals were identified with one exception. One sample which was retrieved as an affected did not have the biochemical or genetic abnormality of X-ALD and thus is considered an error in sample identity. These studies clearly show that the method is highly sensitive and accurate in identifying individuals with a defect in peroxisomal β-oxidation such as X-ALD.

KW - 1-Hexacosanoyl-2-lysophosphorylcholine (26:0-lyso-PC)

KW - Combined liquid chromatography-tandem mass spectrometry (LC-MS/MS)

KW - Lyso-phosphatidyl-choline (lyso-PC)

KW - Multiple reaction monitoring (MRM)

KW - Newborn screening

KW - Peroxisomal disorders

KW - Phospholipids

KW - X-ALD

UR - http://www.scopus.com/inward/record.url?scp=67349206087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349206087&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2009.03.010

DO - 10.1016/j.ymgme.2009.03.010

M3 - Article

VL - 97

SP - 212

EP - 220

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 3

ER -